12-1-2017

Hypertension Associated with Atrial Fibrillation

Wilbert Aronow
New York Medical College

Follow this and additional works at: https://touroscholar.touro.edu/nymc_fac_pubs

Part of the Cardiology Commons

Recommended Citation
Hypertension associated with atrial fibrillation

Wilbert S. Aronow

Division of Cardiology, Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY, USA

Correspondence to: Wilbert S. Aronow, MD, FACC, FAHA. Professor of Medicine, Division of Cardiology, Westchester Medical Center and New York Medical College, Macy Pavilion, Room 141, Valhalla, NY 10595, USA. Email: wsaronow@aol.com.

Submitted Sep 25, 2017. Accepted for publication Oct 20, 2017.
doi: 10.21037/atm.2017.10.33
View this article at: http://dx.doi.org/10.21037/atm.2017.10.33

Hypertension (1) and atrial fibrillation (2,3) both increase with age. Both hypertension and atrial fibrillation are associated with an increased incidence of stroke, heart failure, and mortality (1-3). Hypertension and left ventricular hypertrophy caused by hypertension are major risk factors for atrial fibrillation (1). Hypertension is present in more than 80% of patients with atrial fibrillation (4).

At 44-month follow-up of 2,384 older patients, atrial fibrillation was a significant risk factor for new thromboembolic stroke with a risk ratio of 3.2, and left ventricular hypertrophy associated with hypertension was a significant independent risk factor for thromboembolic stroke with a risk ratio of 2.8 (5). At 36-month follow-up of 312 older patients with chronic atrial fibrillation, left ventricular hypertrophy associated with hypertension was a significant independent risk factor for thromboembolic stroke with a risk ratio of 2.8 (6). Hypertension is one of the risk factors for development of thromboembolic stroke in patients with atrial fibrillation in the CHADS₂ (7) and CHA₂DS₂-VASc (8) scoring systems for risk of stroke.

Hypertension is present in 74% of patients with congestive heart failure and in 77% of patients with a first stroke (9). Atrial fibrillation was present in 37% of 355 patients, mean age 80 years, with prior myocardial infarction, congestive heart failure, and a reduced left ventricular ejection fraction and in 33% of 296 patients, mean age 82 years, with prior myocardial infarction, congestive heart failure, and a preserved left ventricular ejection fraction (10).

Hypertension is associated with left ventricular hypertrophy, impaired diastolic filling of the left ventricle, increased left atrial pressure, left atrial hypertrophy and enlargement, increased atrial fibrillation, increased atrial ectopic activity, and slowing of intra- and interatrial electrical conduction velocities (11). These changes in cardiac structure and physiology predispose to atrial fibrillation developing and increasing the risk of thromboembolic events (11). In patients who have atrial fibrillation, the presence of hypertension increases the incidence of stroke by an additional 2 to 3 times (12,13).

Adequate control of hypertension is indicated to reduce the risk of developing atrial fibrillation. A meta-analysis was performed in 11 randomized studies including 56,308 patients which investigated whether treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers reduced the development of atrial fibrillation (14). The studies included four trials of patients with congestive heart failure, three trials of patients with hypertension, two trials after cardioversion for atrial fibrillation, and two trials after myocardial infarction. Overall, the use of angiotensin-converting enzyme inhibitors significantly reduced the risk of developing atrial fibrillation by 28%, and the use of angiotensin receptor blockers significantly reduced the risk of developing atrial fibrillation by 29%. The prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers seemed limited to patients with heart failure who had a 44% significant reduction in the development of atrial fibrillation and to patients with hypertension and left ventricular hypertrophy who had a 29% significant reduction in the development of atrial fibrillation (14). The angiotensin-converting enzyme inhibitors probably reduce the risk of developing atrial fibrillation by reversing changes in cardiac structure and function (14). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in animal models of heart failure have been demonstrated to reduce left atrial dilation, left atrial dysfunction, left atrial fibrosis, and shortening of the atrial refractory period, which should lead to a decrease
in the risk of atrial fibrillation (14,15).

In the Losartan Intervention for Endpoint (LIFE) trial, 8,851 patients with hypertension and electrocardiographic left ventricular hypertrophy without atrial fibrillation were randomized to losartan or atenolol and followed for a mean duration of 4.8 years (16). Compared with atenolol, the incidence of atrial fibrillation that developed was significantly reduced by 33% despite similar blood pressure reduction by losartan and atenolol (16). The incidence of stroke in the patients who developed new-onset atrial fibrillation was also 51% lower in patients treated with losartan than in patients treated with atenolol (16). In the LIFE study, 342 patients with hypertension, left ventricular hypertrophy, and atrial fibrillation were randomized to losartan or to atenolol and followed up for 1,471 patient years (17). The primary composite endpoint of cardiovascular mortality, stroke, and myocardial infarction was significantly reduced by 42% in the patients treated with losartan in these patients with hypertension, left ventricular hypertrophy, and atrial fibrillation (17).

Another meta-analysis was performed in 11 randomized controlled studies which included 55,971 patients which investigated whether treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers reduced the risk of development of atrial fibrillation (18). In three hypertension studies including 26,084 patients, compared with other antihypertensive drugs, treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker significantly reduced the risk of developing atrial fibrillation by 23% (18). In three studies of 10,305 patients with congestive heart failure, treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker significantly reduced the risk of developing atrial fibrillation by 32% (18). In three studies of 317 patients after electrical conversion of atrial fibrillation, treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker significantly reduced the risk of developing atrial fibrillation by 51% (18). In two studies of 19,288 patients after myocardial infarction, treatment with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker significantly reduced the risk of developing atrial fibrillation by 10% (18).

A third meta-analysis included ten randomized controlled trials in 42,892 patients with hypertension (19). In these trials, 20,491 patients were randomized to treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and 22,401 patients to treatment with beta blockers or with calcium channel blockers. Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers significantly reduced the incidence of atrial fibrillation by 52% when compared to treatment with calcium channel blockers and by 61% when compared with beta blockers (19). Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers also significantly reduced the incidence of congestive heart failure by 14% when compared with treatment with calcium channel blockers or beta blockers but did not significantly reduce the incidence of new atrial fibrillation, cardiac death, myocardial infarction, and stroke when compared with treatment with calcium channel blockers or beta blockers (19).

Follow-up electrocardiograms were available for 25,332 of 33,357 patients (76%) randomized to lisinopril, chlorthalidone, or amloodipine in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (20). The incidence of new atrial fibrillation or atrial flutter did not differ significantly between patients treated with these three different antihypertensive drugs. However, the incidence of new atrial fibrillation or atrial flutter in 6,392 patients treated with doxazosin was significantly increased 1.3 times than in 11,695 patients treated with chlorthalidone (20).

In patients with hypertension, antihypertensive medications reduce the risk of stroke and of atrial fibrillation (1). Because patients with atrial fibrillation are at high risk for developing stroke, patients with atrial fibrillation and hypertension should especially have their blood pressure adequately controlled by antihypertensive drug treatment.

Acknowledgements

None.

Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.

References


